Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, a) 30 capsules bottles, NDC 60429-165-30; b) 90 capsules bottles, NDC 60429-165-90, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Packaged by GSMS, Incorporated, Camarillo, CA 93012.
Published July 3, 2024 · Recall initiated: May 13, 2024
Summary
FDA records drug Class II recall D-0568-2024, published July 3, 2024 and initiated May 13, 2024. Recalling firm: Golden State Medical Supply Inc.; Status: Terminated; Reported quantity: 21,655 (30 count bottle), 34,149 (90 count bottle); Lot: Lot: a) GS045371, Exp: 01/31/2025; b) GS045910, Exp. 01/31/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the proposed interim limit.
What to do
Voluntary: Firm initiated · Letter
Get an email if DULOXETINE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- DULOXETINE
- Manufacturer
- Golden State Medical Supply Inc.
- Distributor
- Nationwide in the U.S.
- Lot
- Lot: a) GS045371, Exp: 01/31/2025; b) GS045910, Exp. 01/31/2025
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDADuloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000June 17, 2026
- FDADuloxetine Delayed-Release Capsules, USP, 30mg, 1000 Capsule bottles, Rx only, Manufactured. by: TowaJune 17, 2026
- FDADuloxetine DR Capsules, 30 mg, 30 count bottles, Rx, Relabeled by: Enovachem Pharmaceuticals, Torrance, CAJune 10, 2026
- FDADuloxetine Delayed-Release Capsules, 60 mg, Rx Only, 30 capsules, Marketed by: Ajanta Pharma USA Inc.,May 13, 2026
- FDAZilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only,July 3, 2024
- FDASinuFrin Decongestant (oxymetazoline HCl) Nasal Solution Nasal Decongestant, Decongestant Relief for up to 12July 3, 2024
Questions about this recall
Was Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, a) 30 capsules bottles, NDC 60429-165-30; b) 90 capsules bottles, NDC 60429-165-90, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Packaged by GSMS, Incorporated, Camarillo, CA 93012. recalled?
Yes. FDA published recall D-0568-2024 on July 3, 2024. Reported hazard: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the proposed interim limit.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: DULOXETINE.